ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

DCPC Board Approves Nine Concepts, New Small Cancer Control Grants, Rerelease Of FDA For Nutrition Core Grants

January 20, 1984

Continuing Resolution Expires March 27; NIH, NCI Hope For Budget Compromise

March 15, 2013

NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer

August 26, 2005

In Brief: Caplan Receives NSB Public Service Award

March 28, 2014

FASEB: Focus on Research Funding, Not PR

June 14, 2013

Report Criticizes NIH Grant Review

June 16, 1995